Phase 2a, Multi-Center, Open Label, Randomized, Feasibility/Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Subjects Undergoing Elective PCI [percutaneous coronary intervention] After Pretreatment With Clopidogrel and Aspirin.

Trial Profile

Phase 2a, Multi-Center, Open Label, Randomized, Feasibility/Safety Study Comparing REG1 Anticoagulation System With Unfractionated Heparin in Subjects Undergoing Elective PCI [percutaneous coronary intervention] After Pretreatment With Clopidogrel and Aspirin.

Completed
Phase of Trial: Phase II

Latest Information Update: 04 Jun 2015

At a glance

  • Drugs Anivamersen-pegnivacogin (Primary) ; Heparin
  • Indications Coronary artery disease; Coronary stent thrombosis; Coronary thrombosis
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Acronyms REVERSAL-PCI
  • Sponsors Regado Biosciences
  • Most Recent Events

    • 26 Jul 2010 Results have been published in Circulation, according to a Regado Biosciences media release.
    • 15 Mar 2010 Results were presented at the 59th Annual Scientific Session of the American College of Cardiology.
    • 31 Aug 2009 Positive results from this trial is the basis for proceeding to the next phase (IIb) of development (see trial profile 700046757).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top